Perifosine enhances mTORC1-targeted cancer therapy by activation of GSK3β in NSCLC cells

Cancer Biology and Therapy

Volumn 13, Issue 11, 2012, Pages 1009-1017

  Ma, Zhuo ^a   Zhu, Lingjun ^a   Luo, Xuan ^a   Zhai, Sulan ^a   Li, Ping ^a   Wang, Xuerong ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

Author keywords

GSK3 ; Lung cancer; mTOR; Perifosine; Rapamycin

Indexed keywords

EVEROLIMUS; GLYCOGEN SYNTHASE KINASE 3BETA; LITHIUM CHLORIDE; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; PERIFOSINE; RAPAMYCIN; SMALL INTERFERING RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER RESISTANCE; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG FORMULATION; ENZYME ACTIVITY; ENZYME INACTIVATION; FEMALE; GENE EXPRESSION; GENE TARGETING; GROWTH INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LUNG NON SMALL CELL CANCER; MOLECULARLY TARGETED THERAPY; MOUSE; NONHUMAN; PROTEIN PHOSPHORYLATION; RECEPTOR DOWN REGULATION; TUMOR SUPPRESSOR GENE; TUMOR XENOGRAFT;

ANIMALS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; FEMALE; GENE KNOCKDOWN TECHNIQUES; GLYCOGEN SYNTHASE KINASE 3; HUMANS; LUNG NEOPLASMS; MICE; MICE, NUDE; MOLECULAR TARGETED THERAPY; PHOSPHORYLATION; PHOSPHORYLCHOLINE; PROTEINS; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; SIROLIMUS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84865841205     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.20989     Document Type: Article

References (36)

1. Yu Y, Yoon SO, Poulogiannis G, Yang Q, Ma XM, Villén J, et al. Phosphoproteomic analysis identifies Grb10 as an mTORC1 substrate that negatively regulates insulin signaling. Science 2011; 332:1322-6; PMID:21659605; http://dx.doi.org/10.1126/science.1199484.
2. Hsu PP, Kang SA, Rameseder J, Zhang Y, Ottina KA, Lim D, et al. The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling. Science 2011; 332:1317-22; PMID:21659604; http://dx.doi.org/10.1126/science.1199498.
3. Yea SS, Fruman DA. Cell signaling. New mTOR targets Grb attention. Science 2011; 332:1270-1; PMID:21659593; http://dx.doi.org/10.1126/science. 1208071.
4. Fasolo A, Sessa C. Current and future directions in mammalian target of rapamycin inhibitors development. Expert Opin Investig Drugs 2011; 20:381-94; PMID:21299441; http://dx.doi.org/10.1517/13543784.2011.541154.
5. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, et al.; RECORD-1 Study Group. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008; 372:449-56; PMID:18653228; http://dx.doi.org/10.1016/S0140-6736(08)61039-9.
6. Hess G, Herbrecht R, Romaguera J, Verhoef G, Crump M, Gisselbrecht C, et al. Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. J Clin Oncol 2009; 27:3822-9; PMID:19581539; http://dx.doi.org/10.1200/JCO.2008. 20.7977.
7. Mishra R. Glycogen synthase kinase 3beta: can it be a target for oral cancer. Mol Cancer 2010; 9:144; PMID:20537194; http://dx.doi.org/10.1186/1476- 4598-9-144.
8. Wang Z, Iwasaki M, Ficara F, Lin C, Matheny C, Wong SH, et al. GSK-3 promotes conditional association of CREB and its coactivators with MEIS1 to facilitate HOX-mediated transcription and oncogenesis. Cancer Cell 2010; 17:597-608; PMID:20541704; http://dx.doi.org/10.1016/j.ccr.2010.04.024.
9. Sutherland C, Leighton IA, Cohen P. Inactivation of glycogen synthase kinase-3beta by phosphorylation: new kinase connections in insulin and growth-factor signalling. Biochem J 1993; 296:15-9; PMID:8250835.
10. Hur EM, Zhou FQ. GSK3 signalling in neural development. Nat Rev Neurosci 2010; 11:539-51; PMID:20648061; http://dx.doi.org/10.1038/nrn2870.
11. Zheng H, Saito H, Masuda S, Yang X, Takano Y. Phosphorylated GSK3beta-ser9 and EGFR are good prognostic factors for lung carcinomas. Anticancer Res 2007; 27:3561-9; PMID:17972518.
12. Gills JJ, Dennis PA. Perifosine: update on a novel Akt inhibitor. Curr Oncol Rep 2009; 11:102-10; PMID:19216841; http://dx.doi.org/10.1007/s11912-009- 0016-4.
13. Rahmani M, Reese E, Dai Y, Bauer C, Payne SG, Dent P, et al. Coadministration of histone deacetylase inhibitors and perifosine synergistically induces apoptosis in human leukemia cells through Akt and ERK1/2 inactivation and the generation of ceramide and reactive oxygen species. Cancer Res 2005; 65:2422-32; PMID:15781658; http://dx.doi.org/10.1158/0008-5472.CAN- 04-2440.
14. Dasmahapatra GP, Didolkar P, Alley MC, Ghosh S, Sausville EA, Roy KK. In vitro combination treatment with perifosine and UCN-01 demonstrates synergism against prostate (PC-3) and lung (A549) epithelial adenocarcinoma cell lines. Clin Cancer Res 2004; 10:5242-52; PMID:15297428; http://dx.doi.org/10.1158/1078- 0432.CCR-03-0534.
15. Festuccia C, Gravina GL, Muzi P, Millimaggi D, Dolo V, Vicentini C, et al. Akt down-modulation induces apoptosis of human prostate cancer cells and synergizes with EGFR tyrosine kinase inhibitors. Prostate 2008; 68:965-74; PMID:18361408; http://dx.doi.org/10.1002/pros.20757.
16. Nyåkern M, Cappellini A, Mantovani I, Martelli AM. Synergistic induction of apoptosis in human leukemia T cells by the Akt inhibitor perifosine and etoposide through activation of intrinsic and Fas-mediated extrinsic cell death pathways. Mol Cancer Ther 2006; 5:1559-70; PMID:16818515; http://dx.doi.org/10.1158/1535-7163.MCT-06-0076.
17. Fu L, Kim YA, Wang X, Wu X, Yue P, Lonial S, et al. Perifosine inhibits mammalian target of rapamycin signaling through facilitating degradation of major components in the mTOR axis and induces autophagy. Cancer Res 2009; 69:8967-76; PMID:19920197; http://dx.doi.org/10.1158/0008-5472.CAN-09-2190.
18. Hideshima T, Catley L, Yasui H, Ishitsuka K, Raje N, Mitsiades C, et al. Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells. Blood 2006; 107:4053-62; PMID:16418332; http://dx.doi.org/10.1182/blood-2005-08-3434.
19. Elrod HA, Lin YD, Yue P, Wang X, Lonial S, Khuri FR, et al. The alkylphospholipid perifosine induces apoptosis of human lung cancer cells requiring inhibition of Akt and activation of the extrinsic apoptotic pathway. Mol Cancer Ther 2007; 6:2029-38; PMID:17604333; http://dx.doi.org/10.1158/1535- 7163.MCT-07-0004.
20. Papa V, Tazzari PL, Chiarini F, Cappellini A, Ricci F, Billi AM, et al. Proapoptotic activity and chemosensitizing effect of the novel Akt inhibitor perifosine in acute myelogenous leukemia cells. Leukemia 2008; 22:147-60; PMID:17928881; http://dx.doi.org/10.1038/sj.leu.2404980.
21. Tazzari PL, Tabellini G, Ricci F, Papa V, Bortul R, Chiarini F, et al. Synergistic proapoptotic activity of recombinant TRAIL plus the Akt inhibitor Perifosine in acute myelogenous leukemia cells. Cancer Res 2008; 68:9394-403; PMID:19010914; http://dx.doi.org/10.1158/0008-5472.CAN-08-2815.
22. Wang X, Yue P, Kim YA, Fu H, Khuri FR, Sun SY. Enhancing mammalian target of rapamycin (mTOR)-targeted cancer therapy by preventing mTOR/raptor inhibition-initiated, mTOR/rictor-independent Akt activation. Cancer Res 2008; 68:7409-18; PMID:18794129; http://dx.doi.org/10.1158/0008-5472.CAN-08-1522.
23. Wang X, Hawk N, Yue P, Kauh J, Ramalingam SS, Fu H, et al. Overcoming mTOR inhibition-induced paradoxical activation of survival signaling pathways enhances mTOR inhibitors' anticancer efficacy. Cancer Biol Ther 2008; 7:1952-8; PMID:18981735; http://dx.doi.org/10.4161/cbt.7.12.6944.
24. Wang X, Sun SY. Enhancing mTOR-targeted cancer therapy. Expert Opin Ther Targets 2009; 13:1193-203; PMID:19694499; http://dx.doi.org/10.1517/ 14728220903225008.
25. Wang X, Yue P, Chan CB, Ye K, Ueda T, Watanabe-Fukunaga R, et al. Inhibition of mammalian target of rapamycin induces phosphatidylinositol-3- kinase-dependent and Mnk-mediated eukaryotic translation initiation factor 4E phosphorylation. Mol Cell Biol 2007; 27:7405-13; PMID:17724079; http://dx.doi.org/10.1128/MCB.00760-07.
26. Wang X, Hawk N, Yue P, Kauh J, Ramalingam SS, Fu H, et al. Overcoming mTOR inhibition-induced paradoxical activation of survival signaling pathways enhances mTOR inhibitors' anticancer efficacy. Cancer Biol Ther 2008; 7:1952-8; PMID:18981735; http://dx.doi.org/10.4161/cbt.7.12.6944.
27. Kondapaka SB, Singh SS, Dasmahapatra GP, Sausville EA, Roy KK. Perifosine, a novel alkylphospholipid, inhibits protein kinase B activation. Mol Cancer Ther 2003; 2:1093-103; PMID:14617782.
28. Witzig TE, Kaufmann SH. Inhibition of the phosphatidylinositol-3-kinase/ mammalian target of rapamycin pathway in hematologic malignancies. Curr Treat Options Oncol 2006; 7:285-94; PMID:16916489; http://dx.doi.org/10.1007/s11864- 006-0038-1.
29. Cirstea D, Hideshima T, Rodig S, Santo L, Pozzi S, Vallet S, et al. Dual inhibition of akt/mammalian target of rapamycin pathway by nanoparticle albumin-bound-rapamycin and perifosine induces antitumor activity in multiple myeloma. Mol Cancer Ther 2010; 9:963-75; PMID:20371718; http://dx.doi.org/10. 1158/1535-7163.MCT-09-0763.
30. Martinez A. Preclinical efficacy on GSK-3 inhibitors: towards a future generation of powerful drugs. Med Res Rev 2008; 28:773-96; PMID:18271054; http://dx.doi.org/10.1002/med.20119.
31. Patel S, Woodgett J. Glycogen synthase kinase-3 and cancer: good cop, bad cop? Cancer Cell 2008; 14:351-3; PMID:18977324; http://dx.doi.org/10.1016/j. ccr.2008.10.013.
32. Stambolic V, Woodgett JR. Mitogen inactivation of glycogen synthase kinase-3beta in intact cells via serine 9 phosphorylation. Biochem J 1994; 303:701-4; PMID:7980435.
33. Sun SY, Rosenberg LM, Wang X, Zhou Z, Yue P, Fu H, et al. Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. Cancer Res 2005; 65:7052-8; PMID:16103051; http://dx.doi.org/10.1158/0008-5472.CAN-05-0917.
34. Wang L, Lin HK, Hu YC, Xie S, Yang L, Chang C. Suppression of androgen receptor-mediated transactivation and cell growth by the glycogen synthase kinase 3 beta in prostate cells. J Biol Chem 2004; 279:32444-52; PMID:15178691; http://dx.doi.org/10.1074/jbc.M313963200.
35. Dubrovska A, Kim S, Salamone RJ, Walker JR, Maira SM, García-Echeverría C, et al. The role of PTEN/Akt/PI3K signaling in the maintenance and viability of prostate cancer stem-like cell populations. Proc Natl Acad Sci USA 2009; 106:268-73; PMID:19116269; http://dx.doi.org/10. 1073/pnas.0810956106.
36. Liao X, Zhang L, Thrasher JB, Du J, Li B. Glycogen synthase kinase-3beta suppression eliminates tumor necrosis factor-related apoptosis-inducing ligand resistance in prostate cancer. Mol Cancer Ther 2003; 2:1215-22; PMID:14617795.